We would love to hear your thoughts about our site and services, please take our survey here.
Operations now massively expanded to gear up for the potentially giant demand from the CR deal and STC, writings on the wall. £10m end of year guidance will be smashed imo. GB has a habit of underpromising and overdelivering.
Certainly agree, the China Resources deal will be the game changer. Very much looking forward to finding out the figures involved in that. With STC also factored into the equation could be looking at a massive 2022 with everything now in place.
Very strong continued growth! Net Assets in H1 increased from £4.3m to £25.3m as of 30 June 2021 with second half revevenues expected to be a 'multiple of H1'. Serious launchpad for the company to now expand and grow into a global monster. Good to see STC revenues will be really ramping up as a 'tier 1' marketing campaign is launched in Q4. Great work team!
Does seem like there is something seriously wrong with this Sangidiot who just seems to consistantly spout garbage every time i check this bb. Must live a fun life
So much happening with Microtox PD being implemented aroind the world and Microtox BT trials ongoing. Revenues ramping up from LabSkin as well and big growth expected over the next couple of years. Will be interesting to see the deals being held under NDA's as well especially with China Resources. Lots of big milestones incoming this year. We'll see who has the last laugh ;)
Got to feel for some of the braindead derampers here gunning for a lower entry lol
Lots of transformational news to come over the next couple of years, succesful 'proof of concept' will revolutionize the pharma space and how neurodegenerative diseases are treated and will very likely result in a buyout in the many billions imo.
Well the problem with treatments for most neurodegenrative diseases like Alzheimers, Parkinsons, MS, etc is their inability to cross the blood brain barrier. Administering Foralumab nasally however, allows t-regs to be upregulated which are then able to cross the BBB providing an effective treatment for many of these diseases. From what i understand, once long term tolerability of the drug has been proven safe (~6months of dosing i believe) then patients in these groups (Alzheimers, Parkinsons, etc) can begin dosing and be brought into the trial. In my view, the proving of this science will be the real value inflection point. Of course timescales are hard to judge, so personally i prefer to hold conviction in the science and wait for the thesis to be proven and thus de-risked.
Dont get me wrong, i do think certain aspects like shareholder communication could be improved. But the treatments/assets TILS hold are very unique and are in areas of serious value in the pharma space, which imo vastly shifts the risk/reward in favor of the upside (especially so from these levels).
Owning a potential therapy that has been proven to cross the blood-brain barrier to treat neurodenerative diseases should not be overlooked, this is very impressive and of course, valuable. And Milciclib, which has completed many P1 AND P2 trials demonstrating a clinical benefit rate over 64.3% has the ability to actually treat the underlying cause of many advanced cancers, this is in an area where there are little to no treatment options for patients other than chemotherapy!
The fact GC holds a significant number of shares and has taken payment in shares, suggests how confident the BOD are in the success of the company.
In my view, holding a stake in these valuable assets will be well worth playing the long game, despite short term fluctuations etc. Each to their own of course.
Tempted to take another chunk at these levels, unbelievably undervalued for the assets TILS hold and cashed up until end of next year. Certainly feel for those selling.
As we get nearer to phase 3 in treatments, this will really re-rate. Exciting times to be loading up!
Great progress being made behind the scenes from the sounds of it. Innovative, effective and patented approaches to treating neurodegenerative diseases and even cancer. May take time but the addressable markets are staggering and no competition using this type of approach. Brazil data a good early indication and derisking of the treatment. Patience the name of the game.
Lots of things progressing nicely, great stuff!